Page last updated: 2024-12-10

8-hydroxypinoresinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

8-hydroxypinoresinol: cytoprotective lignan from Forsythia suspensa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
ForsythiagenusA plant genus of the family OLEACEAE. Members contain suspensaside.[MeSH]OleaceaeA plant family of the order Lamiales. The leaves are usually opposite and the flowers usually have four sepals, four petals, two stamens, and two fused carpels that form a single superior ovary.[MeSH]

Cross-References

ID SourceID
PubMed CID3010930
CHEMBL ID471274
CHEBI ID175806
MeSH IDM0537665

Synonyms (15)

Synonym
8-hydroxypinoresinol
(3r,3as,6s,6ar)-3,6-bis(4-hydroxy-3-methoxyphenyl)-3,4,6,6a-tetrahydro-1h-uro[3,4-c]uran-3a-ol
CHEBI:175806
1h,3h-furo[3,4-c]furan-3a(4h)-ol, dihydro-1,4-bis(4-hydroxy-3-methoxyphenyl)-, (1s,3as,4r,6ar)-
(3r,3as,6s,6ar)-3,6-bis(4-hydroxy-3-methoxy-phenyl)-3,4,6,6a-tetrahydro-1h-furo[3,4-c]furan-3a-ol
CHEMBL471274
81426-17-7
2,6-bis(4-hydroxy-3-methoxyphenyl)-3,7-dioxabicyclo[3.3.0]octan-1-ol
(+)-8(1)-hydroxypinoresinol
1-hydroxypinoresinol
4,4',8-trihydroxy-3,3'-dimethoxy-7,9':7',9-diepoxylignan
(+)-1-hydroxylpinoresinol
DTXSID001315412
AKOS040761269
FS-7748
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID403264Antioxidant activity against iodophenol-induced chemiluminescence by horseradish peroxidase/perborate/luminol system2004Journal of natural products, Jul, Volume: 67, Issue:7
New lignans from the roots of Valeriana prionophylla with antioxidative and vasorelaxant activities.
AID403266Vasorelaxant activity on Wistar rat aorta ring assessed as inhibition of phenylephrine-induced contraction at 100 uM in absence of endothelium2004Journal of natural products, Jul, Volume: 67, Issue:7
New lignans from the roots of Valeriana prionophylla with antioxidative and vasorelaxant activities.
AID403263Antioxidant activity assessed as ABTS radical scavenging activity after 15 mins by TEAC method2004Journal of natural products, Jul, Volume: 67, Issue:7
New lignans from the roots of Valeriana prionophylla with antioxidative and vasorelaxant activities.
AID403265Vasorelaxant activity on Wistar rat aorta ring assessed as inhibition of phenylephrine-induced contraction at 100 uM in presence of endothelium2004Journal of natural products, Jul, Volume: 67, Issue:7
New lignans from the roots of Valeriana prionophylla with antioxidative and vasorelaxant activities.
AID721573Estrogenic activity in human MCF7 cells at 5 uM by luciferase reporter gene assay2013European journal of medicinal chemistry, Jan, Volume: 59Lignans from Schisandra sphenathera Rehd. et Wils. and semisynthetic schisantherin A analogues: absolute configuration, and their estrogenic and anti-proliferative activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]